Blood creatinine-to-cystatin-c ratio may track SMA treatment response

Blood creatinine-to-cystatin-c ratio may track SMA treatment response

Blood creatinine-to-cystatin-c ratio, an emerging indicator of muscle mass and strength, may be a promising biomarker of therapeutic response in adults with spinal muscular atrophy (SMA), a study in China shows. Increases in the ratio were significantly associated with gains in motor function, including improved motor skills, hand and arm abilities, and daily living activities, following long-term treatment with Spinraza (nusinersen). “Although …